Welcome to our dedicated page for GNHAY news (Ticker: GNHAY), a resource for investors and traders seeking the latest updates and insights on GNHAY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNHAY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNHAY's position in the market.
Vifor Pharma Group has appointed Alexandros Sigalas as acting Chief Financial Officer and Dr. Oliver P. Kronenberg as Group General Counsel, effective February 1, 2022. Sigalas, a 13-year veteran at Vifor, succeeds Colin Bond, who retired at the end of 2021. Dr. Kronenberg, with extensive experience since joining Vifor in 2008, returns to his role after heading legal at Galenica Group. These strategic appointments aim to enhance financial and legal leadership during the company’s transformational phase.
Vifor Fresenius Medical Care Renal Pharma announced that the European Commission has approved Tavneos® for treating severe, active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) and microscopic polyangiitis (MPA). This approval aligns with the FDA's earlier decision in October 2021. Tavneos® will be available across all EU member states and in Iceland, Liechtenstein, and Norway, with initial launches projected for H1 2022. This approval is based on the successful phase-III ADVOCATE trial, demonstrating superior efficacy compared to standard treatments.
CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), has announced its public tender offer for all registered shares of Vifor Pharma Ltd. at an offer price of USD 179.25 per share. The transaction has received unanimous approval from both companies' Boards of Directors. The main offer period is set to begin on February 2, 2022 and end on March 2, 2022. Interested shareholders are advised to review the offer prospectus available on www.CSLtransaction.com.
CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), announced its public tender offer for Vifor Pharma Ltd. at a cash price of USD 179.25 per share. The offer, which aims to enhance CSL’s portfolio in iron deficiency and nephrology, has been approved by both companies’ Boards of Directors. The main offer period is set to start on February 2, 2022, and end on March 2, 2022. Investors are encouraged to review the tender offer documents for complete terms and conditions, available at www.CSLtransaction.com.
Vifor Pharma announced positive results from its phase-IIIb DIAMOND trial for Veltassa® in heart failure patients with hyperkalemia. The trial, the largest of its kind, showed Veltassa® significantly improved serum potassium levels, allowing 85% of over 1,000 patients to optimize their RAASi therapy. The results support Veltassa®'s role in managing chronic hyperkalemia. Full data will be presented at a major cardiology conference in H1 2022. The trial contributes to ongoing evidence for Veltassa®'s efficacy in heart failure treatments.
The settlement of patent disputes regarding Injectafer® (ferric carboxymaltose) has been reached by Vifor Pharma and American Regent, resolving litigation with Mylan Laboratories and Sandoz. Under the agreement, Mylan and Sandoz will be allowed to market generic versions in the U.S. starting July 1, 2026, pending FDA approval. Dr. Oliver P. Kronenberg stated the company can now focus on addressing iron deficiency anemia, a condition affecting over 1.7 million patients in the U.S.
Vifor Pharma announced the divestment of its finished drug manufacturing operations to CordenPharma, aiming to streamline its structure and focus on nephrology and iron therapies. CordenPharma will take over facilities in Fribourg, Ettingen, and Lisbon, continuing to supply Vifor Pharma products. This strategic move is expected to optimize operational efficiency and strengthen Vifor Pharma's core capabilities. The deal will be closed in Q1 2022, with financial terms undisclosed, and is not expected to impact CSL Limited’s tender offer disclosed earlier.
CSL Limited (ASX: CSL; USOTC: CSLLY) has announced an all-cash offer of US$179.25 per share to acquire Vifor Pharma Ltd (SIX: VIFN) for an aggregate equity value of US$11.7 billion (CHF 10.9 billion). The offer includes a premium of 61% over the closing price of Vifor Pharma on 1 December 2021. Vifor Pharma’s largest shareholder, Patinex AG, holding 23.2% of shares, has agreed to tender its shares. The transaction is anticipated to complete by mid-2022, subject to regulatory approvals and an 80% minimum acceptance rate.
Vifor Pharma Group is currently in discussions with CSL for a potential transaction, though no decisions or timelines have been established. The company has chosen not to comment further on the discussions at this time. Vifor Pharma aims to lead in iron deficiency and nephrology therapies, focusing on innovative patient solutions. The company is headquartered in Switzerland and is publicly listed on the SIX Swiss Exchange under the ticker VIFN.
Vifor Pharma has initiated a phase-IIa clinical trial for vamifeport, an oral ferroportin inhibitor aimed at treating sickle cell disease (SCD). This trial, which is a double-blind, randomized study, seeks to evaluate the safety and efficacy of vamifeport in adults suffering from this debilitating condition. The trial will enroll 25 patients across multiple sites in the U.S., U.K., Lebanon, and Greece, with topline results expected by the end of 2022. Vamifeport has received orphan drug designation from both the FDA and EMA.
FAQ
What is the market cap of GNHAY (GNHAY)?
